Company intelligence / Profile preview

HUINNO

Seoul/Gangnam-gu, Seoul Special City/Gangnam-gu, South Koreahuinno.com ↗

Ownership: Private
Employees: ~32
Development stage: Other

Overview

HUINNO has developed and commercialized wearable devices such as the MEMO Patch and MEMO Watch for long-term ECG and vital sign monitoring. Their proprietary AI-driven MEMO AI platform enables high precision arrhythmia detection with up to a reported ECG reading accuracy of ~97%. The company’s solutions are used in clinical settings for diagnosis and management of chronic cardiac conditions. Clinical partnerships with major hospitals support ongoing validation.

Therapeutic areas: Cardiovascular
Modalities: DeviceArtificial intelligence-based diagnostic platform (for biosignal analysis)Wearable biosensor technology (ECG/PPG sensors)
Industry: Physiological Monitoring

Partnerships

Seoul National University HospitalKorea University HospitalYuhan Corp.

Beyond the preview

Go deeper on HUINNO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUINNO.

Explore the full profile